bimekizumab vs sonelokimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A/F · full Psoriasis pipeline

bimekizumab · Bimzelx

Marketed by UCB

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT03370133 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).

Next expected readout: March 2027 · NCT06506916 (registry estimate)

Reported efficacy

Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2% (met)

Result source: NCT03412747

sonelokimab

Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA

Phase 2 in Psoriasisnanobody
Reliable signal

NCT03384745 · Phase 2 · completed

This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.

Reported efficacy

Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 (Week 12, as compared to Week 0 (baseline)): Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo. (met)

Result source: NCT03384745

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbimekizumabsonelokimab
PASI 7576.9% vs 2.4%+74.5 vs placebo320 mg Q4W · wk 4 · n 321NCT03370133
10 other results
  • 75.9% vs 1.2% 320 mg Q4W · wk 4 · n 349 · Phase 3 · secondary NCT03410992
  • 74% vs 3% Dosage Regimen 1 · wk 4 · n 100 · Phase 3 · secondary NCT06011733
  • 75% vs 0% 320 mg Q4W · wk 4 · n 32 · Phase 3 · secondary NCT05020249
  • 76.5% vs 31.4% 320 mg Q4W + 320 mg Q4W/Q8W · wk 4 · n 319 · Phase 3 · secondary NCT03412747
  • 71% vs 47.3% 320 mg Q4W · wk 4 · n 373 · Phase 3 · secondary NCT03536884
  • 93% vs 4.8% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 83.7% vs 4.8% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 81.4% vs 4.8% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 85% vs 4.8% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 61.5% vs 4.8% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
84.9% vs 90.6%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 90.2% vs 90.6% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 88.5% vs 90.6% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 65.4% vs 90.6% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
PASI 9085% vs 4.8%+80.2 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
48 other results
  • 90.8% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · primary NCT03410992
  • 94% vs 3% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · primary NCT06011733
  • 81.3% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · primary NCT05020249
  • 86.2% vs 47.2% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · primary NCT03412747
  • 85% vs 2.4% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
  • 85.5% vs 74.3% 320 mg Q4W · wk 16 · n 373 · Phase 3 · secondary NCT03536884
  • 79.1% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 72.1% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 67.4% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 75% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · primary NCT02905006
  • 46.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · primary NCT02905006
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 320 mg Q4W · wk 8 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 33 · Phase 2 · secondary NCT03010527
  • 86% vs 0% 320 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 97% vs 45.9% 320 mg Q4W · wk 4 · n 33 · Phase 2 · secondary NCT03010527
  • 96.7% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 30 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 30 · Phase 2 · secondary NCT03010527
  • 96.7% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 30 · Phase 2 · secondary NCT03010527
  • 69.8% vs 0% 480 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 30 · Phase 2 · secondary NCT03010527
  • 96.4% vs 81.1% 160 mg Q4W · wk 12 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 67.6% 160 mg Q4W · wk 8 · n 55 · Phase 2 · secondary NCT03010527
  • 92.7% vs 83.8% 160 mg Q4W · wk 16 · n 55 · Phase 2 · secondary NCT03010527
  • 58.1% vs 0% 160 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 160 mg Q4W · wk 4 · n 55 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 6 · Phase 2 · secondary NCT03010527
  • 83.3% vs 67.6% 320 mg Q4W · wk 8 · n 6 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 6 · Phase 2 · secondary NCT03010527
  • 66.7% vs 45.9% 320 mg Q4W · wk 4 · n 6 · Phase 2 · secondary NCT03010527
  • 62.5% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 8 · Phase 2 · secondary NCT03010527
  • 62.5% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 8 · Phase 2 · secondary NCT03010527
  • 64.3% vs 81.1% 160 mg Q4W / 320 mg Q4W · wk 12 · n 14 · Phase 2 · secondary NCT03010527
  • 57.1% vs 67.6% 160 mg Q4W / 320 mg Q4W · wk 8 · n 14 · Phase 2 · secondary NCT03010527
  • 64.3% vs 83.8% 160 mg Q4W / 320 mg Q4W · wk 16 · n 14 · Phase 2 · secondary NCT03010527
  • 67.5% vs 0% 160 mg w/ LD Q4W · wk 8 · n 40 · Phase 2 · secondary NCT02905006
  • 42.9% vs 45.9% 160 mg Q4W / 320 mg Q4W · wk 4 · n 14 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 64 mg Q4W · wk 12 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 81.1% 64 mg Q4W / 160 mg Q4W · wk 12 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 64 mg Q4W · wk 8 · n 15 · Phase 2 · secondary NCT03010527
  • 73.7% vs 67.6% 64 mg Q4W / 160 mg Q4W · wk 8 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 64 mg Q4W · wk 16 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 83.8% 64 mg Q4W / 160 mg Q4W · wk 16 · n 19 · Phase 2 · secondary NCT03010527
  • 41% vs 0% 64 mg Q4W · wk 8 · n 39 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 64 mg Q4W · wk 4 · n 15 · Phase 2 · secondary NCT03010527
  • 42.1% vs 45.9% 64 mg Q4W / 160 mg Q4W · wk 4 · n 19 · Phase 2 · secondary NCT03010527
69.8% vs 64.2%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 76.5% vs 64.2% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 65.4% vs 64.2% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 36.5% vs 64.2% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
PASI 10061.7% vs 48.9%vs Secukinumab320 mg Q4W · wk 16 · n 373NCT03536884
10 other results
  • 58.6% vs 0% 320 mg Q4W · wk 16 · n 321 · Phase 3 · secondary NCT03370133
  • 68.2% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · secondary NCT03410992
  • 65% vs 0% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · secondary NCT06011733
  • 21.9% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · secondary NCT05020249
  • 60.8% vs 23.9% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · secondary NCT03412747
  • 55.8% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 48.8% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 27.9% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 60% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 28.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
37.7% vs 28.3%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 33.3% vs 28.3% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 25% vs 28.3% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 17.3% vs 28.3% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
sPGA 0/184.1% vs 4.8%+79.3 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
1 other result
  • 81.9% vs 4.8% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
—Not reported
DLQI, change—Trial running · NCT06506916—Not reported

PASI 75

bimekizumab
76.9% vs 2.4%+74.5 vs placebo320 mg Q4W · wk 4 · n 321NCT03370133
10 other results
  • 75.9% vs 1.2% 320 mg Q4W · wk 4 · n 349 · Phase 3 · secondary NCT03410992
  • 74% vs 3% Dosage Regimen 1 · wk 4 · n 100 · Phase 3 · secondary NCT06011733
  • 75% vs 0% 320 mg Q4W · wk 4 · n 32 · Phase 3 · secondary NCT05020249
  • 76.5% vs 31.4% 320 mg Q4W + 320 mg Q4W/Q8W · wk 4 · n 319 · Phase 3 · secondary NCT03412747
  • 71% vs 47.3% 320 mg Q4W · wk 4 · n 373 · Phase 3 · secondary NCT03536884
  • 93% vs 4.8% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 83.7% vs 4.8% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 81.4% vs 4.8% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 85% vs 4.8% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 61.5% vs 4.8% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
sonelokimab
84.9% vs 90.6%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 90.2% vs 90.6% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 88.5% vs 90.6% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 65.4% vs 90.6% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

PASI 90

bimekizumab
85% vs 4.8%+80.2 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
48 other results
  • 90.8% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · primary NCT03410992
  • 94% vs 3% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · primary NCT06011733
  • 81.3% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · primary NCT05020249
  • 86.2% vs 47.2% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · primary NCT03412747
  • 85% vs 2.4% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
  • 85.5% vs 74.3% 320 mg Q4W · wk 16 · n 373 · Phase 3 · secondary NCT03536884
  • 79.1% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 72.1% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 67.4% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 75% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · primary NCT02905006
  • 46.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · primary NCT02905006
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 320 mg Q4W · wk 8 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 33 · Phase 2 · secondary NCT03010527
  • 86% vs 0% 320 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 97% vs 45.9% 320 mg Q4W · wk 4 · n 33 · Phase 2 · secondary NCT03010527
  • 96.7% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 30 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 30 · Phase 2 · secondary NCT03010527
  • 96.7% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 30 · Phase 2 · secondary NCT03010527
  • 69.8% vs 0% 480 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 30 · Phase 2 · secondary NCT03010527
  • 96.4% vs 81.1% 160 mg Q4W · wk 12 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 67.6% 160 mg Q4W · wk 8 · n 55 · Phase 2 · secondary NCT03010527
  • 92.7% vs 83.8% 160 mg Q4W · wk 16 · n 55 · Phase 2 · secondary NCT03010527
  • 58.1% vs 0% 160 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 160 mg Q4W · wk 4 · n 55 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 6 · Phase 2 · secondary NCT03010527
  • 83.3% vs 67.6% 320 mg Q4W · wk 8 · n 6 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 6 · Phase 2 · secondary NCT03010527
  • 66.7% vs 45.9% 320 mg Q4W · wk 4 · n 6 · Phase 2 · secondary NCT03010527
  • 62.5% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 8 · Phase 2 · secondary NCT03010527
  • 62.5% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 8 · Phase 2 · secondary NCT03010527
  • 64.3% vs 81.1% 160 mg Q4W / 320 mg Q4W · wk 12 · n 14 · Phase 2 · secondary NCT03010527
  • 57.1% vs 67.6% 160 mg Q4W / 320 mg Q4W · wk 8 · n 14 · Phase 2 · secondary NCT03010527
  • 64.3% vs 83.8% 160 mg Q4W / 320 mg Q4W · wk 16 · n 14 · Phase 2 · secondary NCT03010527
  • 67.5% vs 0% 160 mg w/ LD Q4W · wk 8 · n 40 · Phase 2 · secondary NCT02905006
  • 42.9% vs 45.9% 160 mg Q4W / 320 mg Q4W · wk 4 · n 14 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 64 mg Q4W · wk 12 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 81.1% 64 mg Q4W / 160 mg Q4W · wk 12 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 64 mg Q4W · wk 8 · n 15 · Phase 2 · secondary NCT03010527
  • 73.7% vs 67.6% 64 mg Q4W / 160 mg Q4W · wk 8 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 64 mg Q4W · wk 16 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 83.8% 64 mg Q4W / 160 mg Q4W · wk 16 · n 19 · Phase 2 · secondary NCT03010527
  • 41% vs 0% 64 mg Q4W · wk 8 · n 39 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 64 mg Q4W · wk 4 · n 15 · Phase 2 · secondary NCT03010527
  • 42.1% vs 45.9% 64 mg Q4W / 160 mg Q4W · wk 4 · n 19 · Phase 2 · secondary NCT03010527
sonelokimab
69.8% vs 64.2%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 76.5% vs 64.2% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 65.4% vs 64.2% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 36.5% vs 64.2% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

PASI 100

bimekizumab
61.7% vs 48.9%vs Secukinumab320 mg Q4W · wk 16 · n 373NCT03536884
10 other results
  • 58.6% vs 0% 320 mg Q4W · wk 16 · n 321 · Phase 3 · secondary NCT03370133
  • 68.2% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · secondary NCT03410992
  • 65% vs 0% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · secondary NCT06011733
  • 21.9% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · secondary NCT05020249
  • 60.8% vs 23.9% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · secondary NCT03412747
  • 55.8% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 48.8% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 27.9% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 60% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 28.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
sonelokimab
37.7% vs 28.3%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 33.3% vs 28.3% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 25% vs 28.3% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 17.3% vs 28.3% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

sPGA 0/1

bimekizumab
84.1% vs 4.8%+79.3 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
1 other result
  • 81.9% vs 4.8% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
sonelokimab
—Not reported

DLQI, change

bimekizumab
—Trial running · NCT06506916
sonelokimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. bimekizumab: 5 of 5 rows · sonelokimab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbimekizumab
Rows use multiple source trials
sonelokimab
IGA 0/1
responder rate · % of participants
Induction
85.3% (n=319) vs 57.2% (n=159) Adalimumab @ 16wk320 mg Q4W + 320 mg Q4W/Q8Wa,b,c,d
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
4 other source trials
92.6% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
92% (n=100) vs 3% (n=33) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
85.5% (n=373) vs 78.6% (n=370) Secukinumab @ 16wk320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
87.5% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
88.2% (n=51) vs 0% (n=52) placebo @ 12wk*120 mge,a,b,c,d
NCT03384745 · Phase 2 · converted to % from 45 Participants as posted
show 3 more doses
77.4% (n=53) vs 0% (n=52) placebo @ 12wk*120 mg
NCT03384745 · Phase 2 · converted to % from 41 Participants as posted
84.6% (n=52) vs 0% (n=52) placebo @ 12wk*60 mg
NCT03384745 · Phase 2 · converted to % from 44 Participants as posted
48.1% (n=52) vs 0% (n=52) placebo @ 12wk*30 mg
NCT03384745 · Phase 2 · converted to % from 25 Participants as posted
Dropout rate
—320 mg Q4Wf
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
—320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
—320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
100%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
10.4%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
15.1%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
0%320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
5%320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
0%64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—
NCT03230292 · Phase 2 · registry result, not featured evidence
—320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
—320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
—320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—120 mgg
NCT03384745 · Phase 2
show 7 more results
—120 mg
NCT03384745 · Phase 2
5.7%120 mg
NCT03384745 · Phase 2
3.9%120 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
1.9%60 mg
NCT03384745 · Phase 2
0%30 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
Discontinued due to AEs
—320 mg Q4Wf
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
—320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
—320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
34.3%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
4%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
6.3%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—
NCT03230292 · Phase 2 · registry result, not featured evidence
—320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
—320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
—320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—120 mgg
NCT03384745 · Phase 2
show 7 more results
—120 mg
NCT03384745 · Phase 2
1.9%120 mg
NCT03384745 · Phase 2
3.9%120 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
0%60 mg
NCT03384745 · Phase 2
0%30 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
Serious AEs
6.1%320 mg Q4Wf
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
1.6%320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
2.5%320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
0.6%320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
1.7%320 mg Q4W
NCT03410992 · Phase 3
0%320 mg Q4W
NCT03410992 · Phase 3
4.7%320 mg Q4W/Q4W
NCT03410992 · Phase 3
0%320 mg Q4W/Q4W
NCT03410992 · Phase 3
3%320 mg Q4W/Q8W
NCT03410992 · Phase 3
0%320 mg Q4W/Q8W
NCT03410992 · Phase 3
3.1%Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
4.2%Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
1%Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
7.2%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
10.2%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
4.9%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
9.8%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
9.8%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
4%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
2.7%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
4.2%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
3.7%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
8.9%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
11.1%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
1.5%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
6.8%320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
0%320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
10%320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
14.3%64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
7%
NCT03230292 · Phase 2 · registry result, not featured evidence
7.7%320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
6.3%160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
6.7%64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
5.9%320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
6.3%320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
0%320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
2.3%480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
2%120 mgg
NCT03384745 · Phase 2
show 7 more results
1.9%120 mg
NCT03384745 · Phase 2
—120 mg
NCT03384745 · Phase 2
—120 mg
NCT03384745 · Phase 2
1.9%60 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
3.8%30 mg
NCT03384745 · Phase 2
Most frequent reported AEs
320 mg Q4Wf
nasopharyngitis 21.8% (placebo 8.4%)
oral candidiasis 15.2% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 2.4%)
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 43 more results
320 mg Q4W
nasopharyngitis 9.3% (placebo 8.4%)
oral candidiasis 8.7% (placebo 0%)
headache 3.4% (placebo 0%)
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
320 mg Q4W
nasopharyngitis 20.3%
oral candidiasis 9.5%
diarrhoea 5.1%
NCT03412747 · Phase 3 · Psoriasis · phase 3
320 mg Q4W/Q8W
nasopharyngitis 16.8%
oral candidiasis 11.8%
upper respiratory tract infection 7.5%
NCT03412747 · Phase 3 · Psoriasis · phase 3
320 mg Q4W
nasopharyngitis 6.6% (placebo 4.7%)
oral candidiasis 6% (placebo 0%)
upper respiratory tract infection 4% (placebo 8.1%)
NCT03410992 · Phase 3
320 mg Q4W
nasopharyngitis 4.3% (placebo 4.7%)
neutropenia 4.3% (placebo 0%)
oral candidiasis 4.3% (placebo 0%)
NCT03410992 · Phase 3
320 mg Q4W/Q4W
oral candidiasis 11.3% (placebo 0%)
upper respiratory tract infection 11.3% (placebo 8.1%)
nasopharyngitis 10.4% (placebo 4.7%)
NCT03410992 · Phase 3
320 mg Q4W/Q4W
body tinea 14.3% (placebo 0%)
neutropenia 14.3% (placebo 0%)
psoriasis 14.3% (placebo 4.7%)
NCT03410992 · Phase 3
320 mg Q4W/Q8W
nasopharyngitis 23% (placebo 4.7%)
oral candidiasis 9% (placebo 0%)
upper respiratory tract infection 8% (placebo 8.1%)
NCT03410992 · Phase 3
320 mg Q4W/Q8W
dental caries 25% (placebo 1.2%)
impetigo 25% (placebo 1.2%)
rib fracture 25% (placebo 0%)
NCT03410992 · Phase 3
Dosage Regimen 1
upper respiratory tract infection 18.5% (placebo 6.1%)
injection site pain 5.4% (placebo 3%)
hyperlipidaemia 3.8% (placebo 6.1%)
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
Dosage Regimen 2
hepatic function abnormal 7.3% (placebo 0%)
eczema 5.2% (placebo 0%)
latent tuberculosis 5.2% (placebo 0%)
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
Dosage Regimen 1
upper respiratory tract infection 21% (placebo 6.1%)
hyperlipidaemia 5% (placebo 6.1%)
injection site pain 5% (placebo 3%)
NCT06011733 · Phase 3 · registry result, not featured evidence
320 mg Q4W
nasopharyngitis 19.3%
oral candidiasis 16.1%
upper respiratory tract infection 8.2%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 14.3%
nasopharyngitis 12.5%
oral candidiasis 10.4%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 15%
nasopharyngitis 6.2%
oral candidiasis 5.8%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q4W/Q8W
corona virus infection 19.5%
oral candidiasis 14.6%
dermatitis contact 9.8%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 5.9%
oral candidiasis 5.9%
dermatitis contact 3.9%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q4W
nasopharyngitis 16.6%
oral candidiasis 13.4%
upper respiratory tract infection 6.2%
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
320 mg Q4W
nasopharyngitis 12.6%
oral candidiasis 10.5%
upper respiratory tract infection 4.3%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
oral candidiasis 16.7%
nasopharyngitis 15.3%
upper respiratory tract infection 9.8%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W
oral candidiasis 13.3%
nasopharyngitis 11.6%
urinary tract infection 6.5%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
nasopharyngitis 9.9%
oral candidiasis 8.5%
corona virus infection 7.8%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 22.2%
arthropod bite 11.1%
basal cell carcinoma 11.1%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 10.6%
oral candidiasis 6.1%
nasopharyngitis 4.5%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W/Q8W
corona virus infection 16.9%
oral candidiasis 8.5%
basal cell carcinoma 3.4%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W
corona virus infection 21.9% (placebo 6.7%)
eczema 6.3% (placebo 0%)
tinea pedis 6.3% (placebo 0%)
NCT05020249 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 0%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 5.3%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 0%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site reaction 5.3%
injection site pain 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320/160 mg
nasopharyngitis 45%
urinary tract infection 25%
alanine aminotransferase increased 10%
NCT04718896 · Phase 2 · registry result, not featured evidence
64/32 mg
nasopharyngitis 33.3%
upper respiratory tract infection 23.8%
pharyngitis 14.3%
NCT04718896 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 18.6%
nasopharyngitis 16.3%
gamma-glutamyltransferase increased 11.6%
NCT03230292 · Phase 2 · registry result, not featured evidence
320 mg Q4W
oral candidiasis 16.5%
nasopharyngitis 12.1%
upper respiratory tract infection 9.9%
NCT03010527 · Phase 2 · registry result, not featured evidence
160 mg Q4W
nasopharyngitis 13.5%
oral candidiasis 11.7%
upper respiratory tract infection 9%
NCT03010527 · Phase 2 · registry result, not featured evidence
64 mg Q4W
hypertension 13.3%
nasopharyngitis 13.3%
psoriasis 13.3%
NCT03010527 · Phase 2 · registry result, not featured evidence
320 mg
nasopharyngitis 23.5%
alanine aminotransferase increased 17.6%
gamma-glutamyltransferase increased 17.6%
NCT03025542 · Phase 2 · registry result, not featured evidence
320 mg + PBO
upper respiratory tract infection 18.8%
hyperkalaemia 12.5%
urinary tract infection 12.5%
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
320 mg Q4W
nasopharyngitis 14% (placebo 4.8%)
oral candidiasis 7% (placebo 0%)
neutropenia 4.7% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
480 mg Q4W
nasopharyngitis 9.3% (placebo 4.8%)
arthralgia 7% (placebo 0%)
headache 2.3% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
160 mg Q4W
gamma-glutamyltransferase increased 7% (placebo 2.4%)
nasopharyngitis 7% (placebo 4.8%)
tonsillitis 4.7% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
160 mg w/ LD Q4W
nasopharyngitis 7.5% (placebo 4.8%)
upper respiratory tract infection 7.5% (placebo 2.4%)
gamma-glutamyltransferase increased 5% (placebo 2.4%)
NCT02905006 · Phase 2 · registry result, not featured evidence
64 mg Q4W
nasopharyngitis 12.8% (placebo 4.8%)
upper respiratory tract infection 12.8% (placebo 2.4%)
arthralgia 5.1% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
120 mgg
nasopharyngitis 7.8% (placebo 7.7%)
pruritus 7.8% (placebo 3.8%)
oral candidiasis 5.9% (placebo 0%)
NCT03384745 · Phase 2
show 3 more results
120 mg
nasopharyngitis 17% (placebo 7.7%)
headache 5.7% (placebo 1.9%)
pruritus 5.7% (placebo 3.8%)
NCT03384745 · Phase 2
60 mg
nasopharyngitis 21.2% (placebo 7.7%)
pruritus 7.7% (placebo 3.8%)
headache 5.8% (placebo 1.9%)
NCT03384745 · Phase 2
30 mg
nasopharyngitis 7.7% (placebo 7.7%)
arthralgia 5.8% (placebo 1.9%)
hypertension 5.8% (placebo 3.8%)
NCT03384745 · Phase 2

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 16 weeks versus 12 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 43 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bimekizumab

sPGA 0/1 84.1% (n=321) vs 4.8% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
81.9% (n=321) vs 4.8% (n=83) placebo @ 12wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
78.2% (n=321) vs 60.7% (n=163) Ustekinumab @ 52wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
IGA 0 58.6% (n=321) vs 0% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
69.6% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
21.9% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
Pain 77.3% (n=229) vs 16.7% (n=54) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
78.8% (n=255) vs 9% (n=67) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
62.5% (n=24) vs 0% (n=10) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
86.1% (n=72) vs 14.3% (n=14) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Itch 76.6% (n=244) vs 13.1% (n=61) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
75.5% (n=278) vs 5.6% (n=72) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
57.7% (n=26) vs 0% (n=12) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
84.1% (n=88) vs 8% (n=25) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Scaling 78.5% (n=246) vs 12.7% (n=63) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
78% (n=286) vs 5.7% (n=70) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
64.3% (n=28) vs 0% (n=13) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
91.6% (n=95) vs 20% (n=30) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Scalp IGA 84.2% (n=285) vs 15.3% (n=72) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
92.3% (n=310) vs 6.8% (n=74) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
86.2% (n=29) vs 7.1% (n=14) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
PASI 90 82.6% (n=161) @ 56wk320 mg Q4W/Q8W
responder rate · % of participants
No placebo or comparator arm
NCT03412747 · Phase 3 · Psoriasis · phase 3
show 21 more results
84.8% (n=158) @ 56wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
91% (n=100) @ 56wk320 mg Q4W/Q8W
NCT03410992 · Phase 3
86.8% (n=106) @ 56wk320 mg Q4W/Q4W
NCT03410992 · Phase 3
77.6% (n=384) @ 144wk320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
80.2% (n=832) @ 144wk320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
0% (n=70) @ 144wk320mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
95% (n=20) @ 16wk320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
84.4% (n=32) @ 16wk320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
70.6% (n=17) @ 16wk320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
90.5% (n=21) @ 16wk64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
53.5% (n=43) @ 4wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 8wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 12wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 16wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 20wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 24wk
NCT03230292 · Phase 2 · registry result, not featured evidence
81.4% (n=43) @ 28wk
NCT03230292 · Phase 2 · registry result, not featured evidence
81.4% (n=43) @ 32wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 36wk
NCT03230292 · Phase 2 · registry result, not featured evidence
76.7% (n=43) @ 40wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 44wk
NCT03230292 · Phase 2 · registry result, not featured evidence
IGA 0/1 83.2% (n=161) @ 56wk320 mg Q4W/Q8W
responder rate · % of participants
No placebo or comparator arm
NCT03412747 · Phase 3 · Psoriasis · phase 3
show 6 more results
82.3% (n=158) @ 56wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
76.8% (n=384) @ 144wk320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
79% (n=832) @ 144wk320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
0% (n=70) @ 144wk320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
95% (n=20) @ 16wk320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
90.5% (n=21) @ 16wk64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
DLQI 0/1 46.9% (n=32) vs 6.7% (n=15) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT05020249 · Phase 3 · registry result, not featured evidence
BSA -83.472% (n=32) vs -3.028% (n=15) placebo @ 16wk320 mg Q4W
absolute change · percentage points
NCT05020249 · Phase 3 · registry result, not featured evidence
PHQ-9 -2.4 vs -2.1 placebo score @ 16wk320 mg Q4W
absolute change · score
NCT05020249 · Phase 3 · registry result, not featured evidence
PASI 75 80% (n=20) @ 4wk320/160 mg
responder rate · % of participants
No placebo or comparator arm
NCT04718896 · Phase 2 · registry result, not featured evidence
show 14 more results
93.8% (n=32) @ 16wk320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
88.2% (n=17) @ 16wk320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
52.4% (n=21) @ 4wk64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
88.4% (n=43) @ 4wk
NCT03230292 · Phase 2 · registry result, not featured evidence
95.3% (n=43) @ 8wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 12wk
NCT03230292 · Phase 2 · registry result, not featured evidence
93% (n=43) @ 16wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 20wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 24wk
NCT03230292 · Phase 2 · registry result, not featured evidence
88.4% (n=43) @ 28wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 32wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 36wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 40wk
NCT03230292 · Phase 2 · registry result, not featured evidence
90.7% (n=43) @ 44wk
NCT03230292 · Phase 2 · registry result, not featured evidence

+ 41 further endpoints in the CSV export.

Hidradenitis Suppurativa

Shared mechanism: IL-17A/F · full Hidradenitis Suppurativa pipeline

bimekizumab · Bimzelx

Marketed by UCB

Approved in Hidradenitis Suppurativamonoclonal antibody
Partial signal

NCT04242446 · Phase 3 · completed

This phase 3 trial randomised 505 adults with moderate to severe hidradenitis suppurativa to one of two bimekizumab regimens or placebo, with participants, care providers, investigators and outcome assessors all masked. The primary endpoint was HiSCR50 response at week 16. Regimen 2 exceeded placebo (47.8% vs 28.7%, p=0.006); for regimen 1 (45.3% vs 28.7%, p=0.030) the 97.5% confidence interval for the odds ratio included 1, and the record states that the testing hierarchy failed on this endpoint. The record reports no power calculation or planned enrolment.

Next expected readout: December 2026 · NCT06921850 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). (met)

Result source: NCT04242498

sonelokimab

Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA

Phase 3 in Hidradenitis Suppurativananobody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07007637 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hidradenitis Suppurativa

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

sonelokimab: no structured comparison results are available for Hidradenitis Suppurativa.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

bimekizumab
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) NCT04242446 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242498 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Psoriatic Arthritis

Shared mechanism: IL-17A/F · full Psoriatic Arthritis pipeline

bimekizumab · Bimzelx

Marketed by UCB

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03370133 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).

Next expected readout: March 2027 · NCT06506916 (registry estimate)

Reported efficacy

Percentage of Participants With American College of Rheumatology 50 (ACR50) Response (From Baseline to Week 16): ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). (met)

Result source: NCT03896581

sonelokimab

Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA

Phase 3 in Psoriatic Arthritisnanobody
Partial signal

NCT06641076 · Phase 3 · active, not recruiting

This was a randomized, triple-masked Phase 3 trial with 960 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-08-10. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: January 2027 · NCT06641089 (registry estimate)

Reported efficacy

Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) (Week 16): Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). (met)

Result source: NCT06641076

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbimekizumabsonelokimab
ACR2062.2% vs 23.8%+38.4 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
5 other results
  • 67% vs 15.8% 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
  • 73.2% vs 19% 160 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 61% vs 19% 160 mg LD · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 51.2% vs 19% 320 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 53.7% vs 19% 16 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
—Trial running · NCT07223138
ACR5043.9% vs 10%+33.9 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
6 other results
  • 43.4% vs 6.8% 160 mg · wk 16 · n 267 · Phase 3 · primary NCT03896581
  • 41.5% vs 7.1% 160 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 46.3% vs 7.1% 160 mg LD · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 24.4% vs 7.1% 320 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 26.8% vs 7.1% 16 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 49.1% vs 38.4% wk 16 · Phase 3 · primary NCT06624228
—Trial running · NCT07223138
PASI 7568.8% vs 10%+58.8 vs placebo160 mg · wk 12 · n 16NCT02969525
3 other results
  • 70.6% vs 10% 160 mg LD · wk 12 · n 17 · Phase 2 · secondary NCT02969525
  • 72.7% vs 10% 320 mg · wk 12 · n 11 · Phase 2 · secondary NCT02969525
  • 57.1% vs 10% 16 mg · wk 12 · n 14 · Phase 2 · secondary NCT02969525
—Trial running · NCT07223138
Minimal disease activity45% vs 13.2%+31.8 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
1 other result
  • 44.2% vs 6% 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
—Trial running · NCT07223138
HAQ-DI, change-0.3 vs -0.1−0.2 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
1 other result
  • -0.4 vs -0.1 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
—Trial running · NCT07223138

ACR20

bimekizumab
62.2% vs 23.8%+38.4 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
5 other results
  • 67% vs 15.8% 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
  • 73.2% vs 19% 160 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 61% vs 19% 160 mg LD · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 51.2% vs 19% 320 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
  • 53.7% vs 19% 16 mg · wk 12 · n 41 · Phase 2 · secondary NCT02969525
sonelokimab
—Trial running · NCT07223138

ACR50

bimekizumab
43.9% vs 10%+33.9 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
6 other results
  • 43.4% vs 6.8% 160 mg · wk 16 · n 267 · Phase 3 · primary NCT03896581
  • 41.5% vs 7.1% 160 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 46.3% vs 7.1% 160 mg LD · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 24.4% vs 7.1% 320 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 26.8% vs 7.1% 16 mg · wk 12 · n 41 · Phase 2 · primary NCT02969525
  • 49.1% vs 38.4% wk 16 · Phase 3 · primary NCT06624228
sonelokimab
—Trial running · NCT07223138

PASI 75

bimekizumab
68.8% vs 10%+58.8 vs placebo160 mg · wk 12 · n 16NCT02969525
3 other results
  • 70.6% vs 10% 160 mg LD · wk 12 · n 17 · Phase 2 · secondary NCT02969525
  • 72.7% vs 10% 320 mg · wk 12 · n 11 · Phase 2 · secondary NCT02969525
  • 57.1% vs 10% 16 mg · wk 12 · n 14 · Phase 2 · secondary NCT02969525
sonelokimab
—Trial running · NCT07223138

Minimal disease activity

bimekizumab
45% vs 13.2%+31.8 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
1 other result
  • 44.2% vs 6% 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
sonelokimab
—Trial running · NCT07223138

HAQ-DI, change

bimekizumab
-0.3 vs -0.1−0.2 vs placebo160 mg Q4W · wk 16 · n 431NCT03895203
1 other result
  • -0.4 vs -0.1 160 mg · wk 16 · n 267 · Phase 3 · secondary NCT03896581
sonelokimab
—Trial running · NCT07223138
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

sonelokimab
Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT06641076 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) NCT05640245 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. bimekizumab: 4 of 4 rows · sonelokimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbimekizumab
Dropout rate
3.7%160 mg Q4Wa
NCT03895203 · Phase 3
show 8 more results
—160 mg Q4W
NCT03895203 · Phase 3
1.5%160 mg
NCT03896581 · Phase 3
0%160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
0.9%160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
—160 mg
NCT03347110 · Phase 2 · registry result, not featured evidence
—160 mg & 160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
—320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
—16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.9%160 mg Q4Wa
NCT03895203 · Phase 3
show 8 more results
—160 mg Q4W
NCT03895203 · Phase 3
0.7%160 mg
NCT03896581 · Phase 3
—160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
—160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
—160 mg
NCT03347110 · Phase 2 · registry result, not featured evidence
—160 mg & 160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
—320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
—16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
Serious AEs
1.9%160 mg Q4Wa
NCT03895203 · Phase 3
show 8 more results
5.6%160 mg Q4W
NCT03895203 · Phase 3
1.9%160 mg
NCT03896581 · Phase 3
0%160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
0%160 mg Q4W
NCT04109976 · Phase 3 · registry result, not featured evidence
7.7%160 mg
NCT03347110 · Phase 2 · registry result, not featured evidence
6.3%160 mg & 160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
0%320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
0%16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
160 mg Q4Wa
nasopharyngitis 9.3% (placebo 4.6%)
upper respiratory tract infection 5.1% (placebo 6.4%)
oral candidiasis 2.1% (placebo 0%)
NCT03895203 · Phase 3
show 6 more results
160 mg Q4W
nasopharyngitis 7% (placebo 4.6%)
upper respiratory tract infection 4.8% (placebo 6.4%)
urinary tract infection 4.8% (placebo 1.4%)
NCT03895203 · Phase 3
160 mg
nasopharyngitis 3.7% (placebo 0.8%)
oral candidiasis 2.6% (placebo 0%)
upper respiratory tract infection 2.2% (placebo 1.5%)
NCT03896581 · Phase 3
160 mg
upper respiratory tract infection 10.9%
nasopharyngitis 10.4%
psoriasis 7.7%
NCT03347110 · Phase 2 · registry result, not featured evidence
160 mg & 160 mg LD
nasopharyngitis 9.5% (placebo 0%)
upper respiratory tract infection 9.5% (placebo 0%)
respiratory tract infection 6.3% (placebo 0%)
NCT02969525 · Phase 2 · registry result, not featured evidence
320 mg
nasopharyngitis 13.8% (placebo 0%)
upper respiratory tract infection 10% (placebo 0%)
pharyngitis 8.8% (placebo 0%)
NCT02969525 · Phase 2 · registry result, not featured evidence
16 mg
nasopharyngitis 7.7% (placebo 0%)
ear infection 5.1% (placebo 0%)
insomnia 5.1% (placebo 0%)
NCT02969525 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bimekizumab

ACR50 43.9% (n=431) vs 10% (n=281) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 6 more results
43.4% (n=267) vs 6.8% (n=133) placebo @ 16wk160 mg
NCT03896581 · Phase 3
41.5% (n=41) vs 7.1% (n=42) placebo @ 12wk160 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
46.3% (n=41) vs 7.1% (n=42) placebo @ 12wk160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
24.4% (n=41) vs 7.1% (n=42) placebo @ 12wk320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
26.8% (n=41) vs 7.1% (n=42) placebo @ 12wk16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
49.1% vs 38.4% risankizumab @ 16wk
NCT06624228 · Phase 3 · sponsor-reported, not registry data
HAQ-DI -0.2567 vs -0.0881 placebo score @ 16wk160 mg Q4W
absolute change · score
NCT03895203 · Phase 3
show 1 more result
-0.3751 vs -0.0701 placebo score @ 16wk160 mg
NCT03896581 · Phase 3
PASI 90 19.8% (n=217) vs 4.3% (n=140) placebo @ 4wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 7 more results
61.3% (n=217) vs 2.9% (n=140) placebo @ 16wk160 mg Q4W
NCT03895203 · Phase 3
26.7% (n=176) vs 0% (n=88) placebo @ 4wk160 mg
NCT03896581 · Phase 3
68.8% (n=176) vs 6.8% (n=88) placebo @ 16wk160 mg
NCT03896581 · Phase 3
62.5% (n=16) vs 10% (n=20) placebo @ 12wk160 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
52.9% (n=17) vs 10% (n=20) placebo @ 12wk160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
45.5% (n=11) vs 10% (n=20) placebo @ 12wk320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
35.7% (n=14) vs 10% (n=20) placebo @ 12wk16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
SF-36 PCS 6.219 vs 2.326 placebo score @ 16wk160 mg Q4W
absolute change · score
NCT03895203 · Phase 3
show 1 more result
7.258 vs 1.413 placebo score @ 16wk160 mg
NCT03896581 · Phase 3
MDA 45% (n=431) vs 13.2% (n=281) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 1 more result
44.2% (n=267) vs 6% (n=133) placebo @ 16wk160 mg
NCT03896581 · Phase 3
Modified Sharp 0.04 vs 0.36 placebo score @ 16wk160 mg Q4W
absolute change · score
NCT03895203 · Phase 3
show 1 more result
0.04 vs 0.32 placebo score @ 16wk160 mg Q4W
NCT03895203 · Phase 3
Enthesitis Resolution 49.8% (n=249) vs 34.9% (n=106) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 1 more result
50% (n=166) vs 35.6% (n=90) placebo @ 16wk160 mg Q4W
NCT03895203 · Phase 3
Dactylitis Resolution 75.6% (n=90) vs 51.1% (n=47) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
ACR20 62.2% (n=431) vs 23.8% (n=281) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 5 more results
67% (n=267) vs 15.8% (n=133) placebo @ 16wk160 mg
NCT03896581 · Phase 3
73.2% (n=41) vs 19% (n=42) placebo @ 12wk160 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
61% (n=41) vs 19% (n=42) placebo @ 12wk160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
51.2% (n=41) vs 19% (n=42) placebo @ 12wk320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
53.7% (n=41) vs 19% (n=42) placebo @ 12wk16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
ACR70 24.4% (n=431) vs 4.3% (n=281) placebo @ 16wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 5 more results
26.6% (n=267) vs 0.8% (n=133) placebo @ 16wk160 mg
NCT03896581 · Phase 3
19.5% (n=41) vs 4.8% (n=42) placebo @ 12wk160 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
31.7% (n=41) vs 4.8% (n=42) placebo @ 12wk160 mg LD
NCT02969525 · Phase 2 · registry result, not featured evidence
14.6% (n=41) vs 4.8% (n=42) placebo @ 12wk320 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 4.8% (n=42) placebo @ 12wk16 mg
NCT02969525 · Phase 2 · registry result, not featured evidence
IGA 0 1 2pt Improvement 28.9% (n=204) vs 3.9% (n=129) placebo @ 4wk160 mg Q4W
responder rate · % of participants
NCT03895203 · Phase 3
show 3 more results
50.5% (n=204) vs 3.9% (n=129) placebo @ 16wk160 mg Q4W
NCT03895203 · Phase 3
30.7% (n=163) vs 1.2% (n=82) placebo @ 4wk160 mg
NCT03896581 · Phase 3
60.7% (n=163) vs 3.7% (n=82) placebo @ 16wk160 mg
NCT03896581 · Phase 3
Patient Assessment of Arthritis Pain -23.6 vs -6.3 placebo score @ 16wk160 mg Q4W
absolute change · score
NCT03895203 · Phase 3
show 1 more result
-27.7 vs -4.5 placebo score @ 16wk160 mg
NCT03896581 · Phase 3

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimekizumab's landscape · sonelokimab's landscape